• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sarcoidosis - Pipeline Review, H1 2012 Product Image

Sarcoidosis - Pipeline Review, H1 2012

  • Published: May 2012
  • 46 pages
  • Global Markets Direct

Sarcoidosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Sarcoidosis - Pipeline Review, H1 2012', provides an overview of the Sarcoidosis therapeutic pipeline. This report provides information on the therapeutic development for Sarcoidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcoidosis. 'Sarcoidosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sarcoidosis.
- A review of the Sarcoidosis products under development by companies and universities/research institutes based on information derived from company READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcoidosis Overview
Therapeutics Development
An Overview of Pipeline Products for Sarcoidosis
Sarcoidosis Therapeutics under Development by Companies
Sarcoidosis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Sarcoidosis Therapeutics – Products under Development by Companies
Sarcoidosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Sarcoidosis Therapeutics Development
Johnson & Johnson
United Therapeutics Corporation
Celgene Corporation
Mondobiotech Holding AG
Sarcoidosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aviptadil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDA001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stelara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simponi - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DasKloster 0112-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DasKloster 0182-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sarcoidosis Therapeutics – Drug Profile Updates
Sarcoidosis Therapeutics – Discontinued Products
Sarcoidosis Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Sarcoidosis, H1 2012
Products under Development for Sarcoidosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Johnson & Johnson, H1 2012
United Therapeutics Corporation, H1 2012
Celgene Corporation, H1 2012
Mondobiotech Holding AG, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Sarcoidosis Therapeutics – Drug Profile Updates
Sarcoidosis Therapeutics – Discontinued Products
Sarcoidosis Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Sarcoidosis, H1 2012
Products under Development for Sarcoidosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos